Security key
52187K200
CYPHERPUNK TECHNOLOGIES INC. - Common Stock, par value $0.001 per share (CYPH)
CUSIP: 52187K200
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 14,716,283
- Total 13F value
- $37,818,851
- Share change
- -49,527
- Put/Call ratio
- 47%
- SEC-reported price per share
- $2.57
- Number of holders
- 46
- Value change
- -$800
- Number of buys
- 17
- Number of sells
- 20
- Shares outstanding
- 124,897,553
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
46
Top holders
10
CYPH full security history
Ownership snapshot
Full 13F holder table
CYPHERPUNK TECHNOLOGIES INC. SEC filings
CYPHERPUNK TECHNOLOGIES INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of CYPH - CYPHERPUNK TECHNOLOGIES INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BeOne Medicines Ltd.
Disclosed value leader
BeOne Medicines Ltd.
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5
13F
Highest disclosed value: $20,943,045
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
BeOne Medicines Ltd. has the largest disclosed position value at $20.94M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BeOne Medicines Ltd.'s linked filing trail.
Disclosed position value
Top 5
BeOne Medicines Ltd.
$20.94M
GILEAD SCIENCES, INC.
$15.16M
BALYASNY ASSET MANAGEMENT L.P.
$6.08M
Samsara BioCapital, LLC
$4.79M
683 Capital Management, LLC
$2.55M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BeOne Medicines Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$20,943,045
7,348,437 shares
|
— | 24 Sep 2021 |
| GILEAD SCIENCES, INC. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$15,159,572
5,319,148 shares
|
— | 10 Apr 2024 |
| PERCEPTIVE ADVISORS LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
3,508,771 shares
|
— | 24 Sep 2021 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
Company
|
—
denominator unverified
|
$6,076,000
3,100,000 shares
|
— | 30 Jun 2024 |
| Samsara BioCapital, LLC |
13F
Company
|
—
denominator unverified
|
$4,787,010
2,442,352 shares
|
— | 30 Jun 2024 |
| 683 Capital Management, LLC |
13F
Company
|
—
denominator unverified
|
$2,548,000
1,300,000 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
46
Shares
14,716,283
Rows available
46
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
46
Q3 2024 holders
46
Holder diff
0
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|